Live Analyst Rating Changes 8087 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Emily Bodnar
HC
Emily Bodnar
H.C. Wainwright
Wall Street Analyst
★★★☆☆
#1636
on 13Foresight · ranked by our own returns
51%
Success Rate
+7.5%
Average Return
21 of 41 calls profitable · +2.3% vs benchmark
📈 Across the calls we could measure, roughly 51% of Emily Bodnar's ratings turned a profit when each position was held for 1 year — averaging +7.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

223 Buy 16 Hold 0 Sell
Emily's Stock Coverage 34 ratings · 2026-07-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
NXTC
NextCure
 Jul 15, 2026 BUY Buy
+238.6% avg upside
10 analysts
$20.00
203.88% Upside
 ·
COAG
Hemab Therapeutics Holdings, Inc.
 Jul 13, 2026 BUY Strong Buy
+21.4% avg upside
5 analysts
$52.00
20.16% Upside
 ·
AGEN
Agenus
 Jul 13, 2026 BUY Strong Buy
+69.8% avg upside
18 analysts
$30.00
490.57% Upside
 ·
NVCR
NovoCure
 Jul 13, 2026 BUY Strong Buy
+203.8% avg upside
11 analysts
$46.00
195.79% Upside
 ·
TGTX
TG Therapeutics
 Jul 13, 2026 BUY Strong Buy
-30.8% avg upside
19 analysts
$77.00
40.28% Upside
 ·
AGIO
Agios Pharma
 Jul 13, 2026 BUY Buy
+51.5% avg upside
29 analysts
$54.00
35.25% Upside
 ·
AUTL
Autolus Therapeutics
 Jul 13, 2026 BUY Strong Buy
+629.5% avg upside
16 analysts
$10.00
589.58% Upside
 -2.0%
TRAX
First Tracks Biotherapeutics Inc
 Jul 10, 2026 BUY Strong Buy
+12.8% avg upside
7 analysts
$44.00
27.98% Upside
 ·
CNTX
Context Therapeutics
 Jun 15, 2026 BUY Strong Buy
+886.2% avg upside
12 analysts
$5.00
702.66% Upside
 +3.6%
SABS
SAB Biotherapeutics
 Jun 15, 2026 BUY Strong Buy
+194.2% avg upside
14 analysts
$10.00
177.76% Upside
 ·
ATOS
Atossa Therapeutics
 Jun 15, 2026 HOLD Strong Buy
+691.9% avg upside
7 analysts
 — ·
ARTV
Artiva Biotherapeutics, Inc.
 Jun 08, 2026 BUY Strong Buy
+259.8% avg upside
7 analysts
$35.00
274.35% Upside
 +39.4%
RCUS
Arcus Biosciences
 Jun 03, 2026 BUY Strong Buy
+18.6% avg upside
20 analysts
$32.00
13.05% Upside
 +26.1%
OLMA
Olema Pharmaceuticals
 Jun 03, 2026 BUY Strong Buy
+221.5% avg upside
16 analysts
$38.00
220.64% Upside
 +16.8%
VTVT
vTv Therapeutics
 May 26, 2026 BUY Strong Buy
+11.2% avg upside
13 analysts
$45.00
41.16% Upside
 +1.8%
PPBT
Purple Biotech
 May 18, 2026 BUY Strong Buy
+2579.6% avg upside
4 analysts
$30.00
2027.68% Upside
 -20.4%
INKT
MiNK Therapeutics
 May 15, 2026 BUY Strong Buy
+92.9% avg upside
6 analysts
$35.00
206.84% Upside
 +3.1%
SNTI
Senti Biosciences
 May 15, 2026 BUY Strong Buy
+800.1% avg upside
7 analysts
$12.00
1140.41% Upside
 +2.0%
ACRV
Acrivon Therapeutics, Inc.
 May 14, 2026 BUY Strong Buy
+576.4% avg upside
13 analysts
$19.00
791.99% Upside
 -7.8%
NKTX
Nkarta
 May 13, 2026 BUY Strong Buy
+596.1% avg upside
16 analysts
$16.00
503.87% Upside
 +4.9%
SANA
Sana Biotechnology
 May 12, 2026 BUY Strong Buy
+176.6% avg upside
14 analysts
$7.00
96.13% Upside
 +16.6%
GNLX
Genelux Corp.
 May 08, 2026 BUY Strong Buy
+525.1% avg upside
7 analysts
$31.00
972.60% Upside
 -2.6%
GERN
Geron
 May 06, 2026 HOLD Strong Buy
+208.4% avg upside
19 analysts
 — -1.3%
IMNN
Imunon
 Apr 02, 2026 BUY Strong Buy
+643.9% avg upside
11 analysts
$25.00
1169.05% Upside
 -16.8%
JSPR
Jasper Therapeutics
 Mar 30, 2026 BUY Buy
+4302.8% avg upside
17 analysts
$20.00
2667.03% Upside
 -46.4%
ANAB
AnaptysBio
 Mar 30, 2026 BUY Strong Buy
+12.7% avg upside
26 analysts
$66.00
5.53% Upside
 +79.8%
VNDA
Vanda
 Feb 23, 2026 BUY Strong Buy
+250.9% avg upside
13 analysts
$18.00
207.61% Upside
 -22.9%
IOBTQ
IO Biotech
 Nov 17, 2025 HOLD Buy
+79815.3% avg upside
6 analysts
 — ·
TSE:BCT
BriaCell Therapeutics
 Oct 13, 2025 BUY Strong Buy
+976.4% avg upside
1 analyst
$56.18
976.42% Upside
 ·
FEMY
Femasys
 Sep 26, 2025 BUY Strong Buy
+1589.8% avg upside
6 analysts
$160.00
4344.40% Upside
 -43.9%
RNAZ
TransCode Therapeutics
 Apr 29, 2025 HOLD Buy
+5494.4% avg upside
2 analysts
 — -30.6%
CNTB
Connect Biopharma Holdings
 Mar 31, 2025 BUY Strong Buy
+177.5% avg upside
12 analysts
$8.00
239.63% Upside
 +376.4%
LTRN
Lantern Pharma
 May 22, 2024 HOLD Strong Buy
+632.8% avg upside
5 analysts
 — -48.1%
SQZB
SQZ Biotechnologies
 Jul 11, 2023 HOLD Buy
+102677.8% avg upside
7 analysts
 — -73.0%
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Emily Bodnar — Frequently Asked Questions
How accurate are Emily Bodnar's stock ratings?
Based on the calls 13Foresight could measure, about 51% of Emily's ratings were profitable over a one-year hold, with an average return of +7.5% per rating, or +2.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Emily ranked on 13Foresight?
Emily Bodnar is currently ranked #1636 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Emily cover?
Emily most recently has ratings on NXTC, COAG, AGEN, NVCR, TGTX, AGIO, AUTL, TRAX, CNTX, SABS, ATOS, ARTV and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.